Opdualag

Chemical Namenivolumab and relatlimab
Dosage FormInjection (intravenous; 240 mg of nivolumab and 80 mg of relatlimab per 20 mL (12 mg and 4 mg per mL))
Drug ClassMultiple
SystemMultiple
CompanyBristol-Myers Squibb
Approval Year2022

Indication

  • For the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.
Last updated on 1/12/2023

More on this drug: Clinical Trials

Document TitleYearSource
Opdualag (nivolumab and relatlimab) Prescribing Information. 2022Bristol-Myers Squibb Company Princeton, NJ
Document TitleYearSource
Assessment report: Opdualag.2022EMA